Sino Biopharm Scoops LaNova In Chinese Pharma’s Biggest Biotech Buyout So Far

Close To $1bn Deal Brings Rich Pipeline

 
• By Dexter Jie Yan
  
Sino Biopharm will rapidly advance bio-startup LaNova's "exploding" pipeline programs after completing an estimated $950.92m tuck-in acquisition of the biotech. (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

More from Scrip